SCHEMBL4665779

SCHEMBL4665779

CN1CCN(CCCOc2ccc(-c3cc(Nc4ccc(N(OC=O)S(=O)(=O)c5ccc(F)cc5)cc4)ncn3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR1 P25024 5/20 0.47
USP2 O75604 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.45
GLA P06280 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
ALOX15 P16050 1/20 0.45
MAPK1 P28482 1/20 0.45
CYP2C19 P33261 1/20 0.45
KMT2A Q03164 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
ABL1 P00519 7/20 0.44
BCR P11274 7/20 0.44
HPGD P15428 1/20 0.40
SRC P12931 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4665832 0.94 MEN1 (0.44) CXCR1USP2ALDH1A1MEN1TP53
SCHEMBL4664247 0.92 CXCR1 (0.42) CXCR1USP2ALDH1A1MEN1TP53
SCHEMBL4664290 0.90 ABL1 (0.43) CXCR1CYP3A4ABL1BCRSRC
SCHEMBL4665825 0.90 ABL1 (0.40) CXCR1USP2ALDH1A1MEN1TP53
SCHEMBL4663993 0.89 ABL1 (0.42) CXCR1USP2ALDH1A1MEN1TP53
SCHEMBL4665665 0.89 ABL1 (0.41) CXCR1USP2ALDH1A1MEN1TP53
SCHEMBL4666086 0.88 HRH3 (0.44) CYP3A4ABL1BCR
SCHEMBL4667432 0.88 CYP3A4 (0.42) CXCR1USP2ALDH1A1MEN1TP53
SCHEMBL4667537 0.88 EGFR (0.41) CXCR1USP2ALDH1A1MEN1TP53
SCHEMBL4666074 0.87 MEN1 (0.45) CXCR1USP2ALDH1A1MEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 CXCR1 3156/4885USP2 2576/4885ALDH1A1 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.